The DEA Decision That Could Create Fortunes

A brand-new market created before our eyes isn’t something you see every day — but that’s exactly what might happen before the end of 2016.

A major change in how America regulates drugs is on the verge of taking place.

This change will create the opportunity to earn huge profits for investors who “get in ahead” of the creation of this market…

A market that is going to include pharmaceuticals and biotechs.

The FDA isn’t the only federal bureaucracy tasked with regulating pharmaceuticals. There’s also the “muscle” behind U.S. drug regulation, and that’s the Drug Enforcement Administration (DEA).

By August 1, the DEA is going to examine what it calls its “schedule” with respect to one controlled substance.

“Schedule” refers to how the DEA classifies drugs. These classes range from Schedule I to Schedule V. Schedule I drugs are the most tightly regulated. In fact, they are practically forbidden on the open market.

Drugs or substances put on Schedule 1:

  1. Have a high potential for abuse.

Since 1972, marijuana has been a Schedule I drug –up there with the likes of heroin — despite having a lower potential for abuse than many other Schedule I drugs, and possible medical uses. I’m not going to argue about the abuse stance –that’s all subjective. But let’s also remember that there are other substances out there with the potential for abuse, like alcohol and caffeine –neither one a Schedule I drug.

What I want to focus on are the potential uses for marijuana from a medicinal standpoint.

Marijuana reacts with several biological systems, allowing vast possibilities in biotech research.


The study of the biological effects of marijuana’s active ingredients has even led to an understanding of a network inside the body called the endocannabinoid system (after the name for the plant: cannabis) controlling both the central nervous and immune systems.


Late last year, however, a letter from multiple senators was sent requesting a re-examination of marijuana regulation. This past spring, the DEA listened, announcing that it will decide whether or not to reclassify the substance as soon as August 1.

August 1. That’s the magic date. And here’s why it could make you a fortune.

Rescheduling marijuana and its derivatives to a milder classification will open floodgates for research and new pharmaceuticals. The total market, including pharmas, could end up being as big as $100 billion per year. Biotech investors could easily see gains for some of these companies in the hundreds and thousands of percent.

A $100 billion medical marijuana market could line your pockets.

It’s prime opportunity for biotech investors. A $100 billion medical marijuana market could line your pockets. And there are lots of ways to play the field.

Plenty of small, publically traded companies that are tied to marijuana use have soared…but I’ve discovered two companies that are still flying under the radar of most investors. I expect the DEA to make the right decision by August 1. If they do, the price of these stocks will hit the ground running.

You can read about the companies in my newest report here. I think they offer you the best chance at making a profit from marijuana-derived medical research.

Again, to find out about the companies I believe will make us the most profit in this potential new market, click here.

To a bright future,

Ray Blanco
for The Daily Reckoning

[Editor’s Note]: Medical Marijuana research is one of the easiest and most profitable things you can do with your money in the following year.

I’ve been following this story very closely for the past few months… waiting for the optimal time to get in.

If you want the chance to risk very little money… with the potential for a huge reward, you need to check out our presentation on this incredible situation.

Click here to find out more.

The Daily Reckoning